Deoxyadenosine

Deoxyadenosine

SCHEMBL5982298

Nc1ncnc2c1ncn2[C@H]1C[C@@H](O)[C@H](CO)O1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.71
SMN1; SMN2 Q16637 2/20 0.70
PNP P00491 1/20 0.70
LMNA P02545 1/20 0.70
TP53 P04637 1/20 0.70
HTT P42858 1/20 0.70
PDE4D Q08499 1/20 0.70
PDE3A Q14432 1/20 0.70
RXFP1 Q9HBX9 1/20 0.70
ADORA3 P0DMS8 3/20 0.63
DPP4 P27487 1/20 0.63
MEN1 O00255 1/20 0.63
SLC28A1 O00337 1/20 0.63
MAP3K7 O43318 1/20 0.63
SLC28A2 O43868 1/20 0.63
GAPDH P04406 1/20 0.63
MAPK1 P28482 1/20 0.63
ADORA2A P29274 1/20 0.63
ADORA2B P29275 1/20 0.63
ADORA1 P30542 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deoxyadenosine SCHEMBL532825 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL193181 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL12222478 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL593935 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL12222447 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL23982174 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL5982291 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL19506291 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL21637036 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53
Deoxyadenosine SCHEMBL19877 1.00 HIF1A (0.71) HIF1ASMN1; SMN2PNPLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634888-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2006-03-15 EP disclosed
EP-1600451-A2 Synthesis of 2'-deoxy-l-nucleosides Pharmasset Limited (US) 2005-11-30 EP disclosed
EP-1600452-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2005-11-30 EP disclosed
US-20050090660-A1 2'-deoxy-L-nucleosides PHARMASSET, INC. 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090660-A1 2'-deoxy-L-nucleosides CCNH, ADAR, NSUN2 HIF1A 2249/4885SMN1; SMN2 2345/4885PNP 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.